LSS

Across TCGA pan-cancer cohorts, LSS mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LSS data layer compared with 30 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LSS mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated LSS expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LSCC, and GBM are the cancer types where LSS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.652	0.400	.001	36	view →
LSCC	DFS	Median	III,IV	0.868	1.000	.027	5	view →
GBM	DFS	Tertile	All	0.286	0.568	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LSS–PDAC (OS)

Open the PDAC breakdown →